96
Views
0
CrossRef citations to date
0
Altmetric
Case Report

A Case of Pneumonia Masking Pleural Malignancy

ORCID Icon, , ORCID Icon, , ORCID Icon, ORCID Icon & ORCID Icon show all
Pages 741-746 | Published online: 02 Jul 2022

References

  • Bibby AC, Maskell NA. Current treatments and trials in malignant pleural mesothelioma. Clin Respir J. 2018;12(7):2161–2169. doi:10.1111/crj.12938
  • Egan AM, McPhillips D, Sarkar S, Breen DP. Malignant pleural effusion. QJM. 2014;107(3):179–184. doi:10.1093/qjmed/hct245
  • Burrows CM, Mathews WC, Colt HG. Predicting survival in patients with recurrent symptomatic malignant pleural effusions: an assessment of the prognostic values of physiologic, morphologic, and quality of life measures of extent of disease. Chest. 2000;117(1):73–78. doi:10.1378/chest.117.1.73
  • Roberts ME, Neville E, Berrisford RG, Antunes G, Ali NJ; Group BTSPDG. Management of a malignant pleural effusion: British Thoracic Society Pleural Disease Guideline 2010. Thorax. 2010;65(Suppl 2):ii32–40. doi:10.1136/thx.2010.136994
  • Hsu C. Cytologic detection of malignancy in pleural effusion: a review of 5255 samples from 3811 patients. Diagn Cytopathol. 1987;3(1):8–12. doi:10.1002/dc.2840030103
  • Salyer WR, Eggleston JC, Erozan YS. Efficacy of pleural needle biopsy and pleural fluid cytopathology in the diagnosis of malignant neoplasm involving the pleura. Chest. 1975;67(5):536–539. doi:10.1378/chest.67.5.536
  • Harris RJ, Kavuru MS, Rice TW, Kirby TJ. The diagnostic and therapeutic utility of thoracoscopy. Chest. 1995;108(3):828–841. doi:10.1378/chest.108.3.828
  • Stathopoulos GT, Kalomenidis I. Malignant pleural effusion: tumor-host interactions unleashed. Am J Respir Crit Care Med. 2012;186(6):487–492. doi:10.1164/rccm.201203-0465PP
  • Henke CA, Leatherman JW. Intrapleurally administered streptokinase in the treatment of acute loculated nonpurulent parapneumonic effusions. Am Rev Respir Dis. 1992;145(3):680–684. doi:10.1164/ajrccm/145.3.680
  • Zhang Y, Li X, Liu J, et al. Diagnostic accuracy of the cancer ratio for the prediction of malignant pleural effusion: evidence from a validation study and meta-analysis. Ann Med. 2021;53(1):558–566. doi:10.1080/07853890.2021.1906943
  • Shi HZ, Liang QL, Jiang J, Qin XJ, Yang HB. Diagnostic value of carcinoembryonic antigen in malignant pleural effusion: a meta-analysis. Respirology. 2008;13(4):518–527. doi:10.1111/j.1440-1843.2008.01291.x
  • Liang QL, Shi HZ, Qin XJ, Liang XD, Jiang J, Yang HB. Diagnostic accuracy of tumour markers for malignant pleural effusion: a meta-analysis. Thorax. 2008;63(1):35–41. doi:10.1136/thx.2007.077958
  • Salaroglio IC, Kopecka J, Napoli F, et al. Potential Diagnostic and Prognostic Role of Microenvironment in Malignant Pleural Mesothelioma. J Thorac Oncol. 2019;14(8):1458–1471. doi:10.1016/j.jtho.2019.03.029
  • Lievense LA, Cornelissen R, Bezemer K, Kaijen-Lambers ME, Hegmans JP, Aerts JG. Pleural Effusion of Patients with Malignant Mesothelioma Induces Macrophage-Mediated T Cell Suppression. J Thorac Oncol. 2016;11(10):1755–1764. doi:10.1016/j.jtho.2016.06.021
  • Budna J, Kaczmarek M, Kolecka-Bednarczyk A, et al. Enhanced Suppressive Activity of Regulatory T Cells in the Microenvironment of Malignant Pleural Effusions. J Immunol Res. 2018;2018:9876014. doi:10.1155/2018/9876014
  • Wahla AS, Uzbeck M, El Sameed YA, Zoumot Z. Managing malignant pleural effusion. Cleve Clin J Med. 2019;86(2):95–99. doi:10.3949/ccjm.86a.17095
  • Decker DA, Dines DE, Payne WS, Bernatz PE, Pairolero PC. The significance of a cytologically negative pleural effusion in bronchogenic carcinoma. Chest. 1978;74(6):640–642. doi:10.1378/chest.74.6.640
  • Migliore M. Efficacy and safety of single-trocar technique for minimally invasive surgery of the chest in the treatment of noncomplex pleural disease. J Thorac Cardiovasc Surg. 2003;126(5):1618–1623. doi:10.1016/s0022-5223(03
  • Özkaya M. Malign plevral efüzyonlarda tek port torakoskopik talk plöredez. Turkish J Clin Lab. 2019. doi:10.18663/tjcl.413937
  • Kim BS, Kim IJ, Kim SJ, Pak K, Kim K. Predictive value of F-18 FDG PET/CT for malignant pleural effusion in non-small cell lung cancer patients. Onkologie. 2011;34(6):298–303. doi:10.1159/000328793